HER-2 negative

P2, N=17, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026

With this technology, we developed trastuzumab deruxtecan, the first DXd-ADC directed toward HER2. Additionally, Dato-DXd showed TROP2-dependent antitumor activity in multiple human cancer cell line-derived and patient-derived xenograft mouse models. Clinically, the global phase III trial targeting hormone receptor-positive, HER2-negative, unresectable or recurrent breast cancer led to its first approval in Japan in December 2024, followed by the approvals in the US and Europe later.

Present findings are from a small sample cohort and need further validation from a larger cohort. The online version contains supplementary material available at 10.1007/s13193-025-02427-0.

Moreover, this "Breast HERV19" expression signature was associated with better prognosis in HR+HER2- eBC, in which its expression was also correlated with biomarkers of sensitivity to anti PD-1 immunotherapy, such as tumor-infiltrating lymphocytes (TILs), PD-L1, and estrogen receptor (ER) expression levels. In eBC, our "Breast HERV19" expression signature makes it possible to isolate a subgroup of HR+HER2- tumors presenting strong immunogenicity, better prognosis, and biological characteristics that suggest a possible benefit from immunotherapy.

The anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) monoclonal antibody ramucirumab was the first antiangiogenic agent approved for HER2-negative metastatic gastric adenocarcinomas and remains a standard second-line treatment either alone or in combination with paclitaxel. Other VEGFR-targeting agents, such as the tyrosine kinase inhibitors (TKI) regorafenib and apatinib, have failed to demonstrate any survival benefit in the first-line settings, while providing modest improvements in pretreated patients, even when combined with Immune Checkpoint Inhibitors (ICI)...Although several biomarker candidates have been explored, reliable predictors are still awaited. This review summarizes current evidence and explores the future of antiangiogenic agents in gastric cancers.

Rhabdomyolysis due to CDK4/6 inhibitor-statin interactions is a rare but potentially life-threatening complication. Vigilant monitoring, timely intervention, and tailored treatment strategies are essential for preventing complications and improving patient outcomes.

P3, N=2138, Active, not recruiting, Canadian Cancer Trials Group | Recruiting --> Active, not recruiting

The ADC showed no significant body weight loss or organ damage in mice, indicating good tolerability. These findings validate a modular strategy combining a Fab scaffold, enzymatic site-specific conjugation, and ABD-mediated half-life extension to generate potent, homogeneous ADCs and nominate T-Fab-ABD(H + L)-DM1 as a promising candidate for HER2-positive cancer therapy.

Disparities between Argentina's health subsystems significantly affect the BC stage at diagnosis and treatment timelines, influencing therapeutic pathways and associated costs. These findings highlight the need for targeted, system-level interventions. While further research is needed to confirm their long-term impact, such efforts may contribute to more equitable care and improved outcomes in LMICs.

In the context of contemporary adjuvant treatment, with patients diagnosed within three years postpartum more likely to receive chemotherapy, ovarian function suppression, and CDK4/6 inhibitors, differences in IDFS associated with time since last childbirth did not result in significantly worse IDFS within the follow-up period (89.0% in patients with PPBC up to 3 years vs. 93.7% in all other patients p = 0.39). These findings indicate that tumors diagnosed within the first year postpartum have significantly elevated RS, and that the period of most aggressive PPBC, as reflected by gene expression profiles, may arise in the more recently postpartum period, in the first 0-3 years postpartum.

P1, N=330, Recruiting, Pyxis Oncology, Inc | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Apr 2027

P2, N=168, Not yet recruiting, Universitaire Ziekenhuizen KU Leuven